[go: up one dir, main page]

ATE318147T1 - Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen - Google Patents

Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen

Info

Publication number
ATE318147T1
ATE318147T1 AT97917121T AT97917121T ATE318147T1 AT E318147 T1 ATE318147 T1 AT E318147T1 AT 97917121 T AT97917121 T AT 97917121T AT 97917121 T AT97917121 T AT 97917121T AT E318147 T1 ATE318147 T1 AT E318147T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
psma
extracellular domain
specific
membrane antigen
Prior art date
Application number
AT97917121T
Other languages
English (en)
Inventor
Gerald P Murphy
Alton L Boynton
Eric H Holmes
William T Tino
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24490004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE318147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE318147T1 publication Critical patent/ATE318147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97917121T 1996-03-25 1997-03-25 Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen ATE318147T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62139996A 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
ATE318147T1 true ATE318147T1 (de) 2006-03-15

Family

ID=24490004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917121T ATE318147T1 (de) 1996-03-25 1997-03-25 Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen

Country Status (10)

Country Link
EP (1) EP0914155B1 (de)
JP (1) JP4295826B2 (de)
AT (1) ATE318147T1 (de)
AU (1) AU725583B2 (de)
CA (1) CA2250141C (de)
DE (1) DE69735294T2 (de)
DK (1) DK0914155T3 (de)
ES (1) ES2260788T3 (de)
IL (1) IL126314A (de)
WO (1) WO1997035616A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
DE69635801T2 (de) 1995-02-24 2006-11-02 Sloan-Kettering Institute For Cancer Research Prostataspezifisches membranes antigen und seine anwendungen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB2328871A (en) * 1997-09-05 1999-03-10 Merck & Co Inc Compositions for inhibiting platelet aggregation
WO1999043710A1 (en) * 1998-02-26 1999-09-02 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
DE69941187D1 (de) * 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
WO2000050457A1 (en) * 1999-02-22 2000-08-31 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
AU783356B2 (en) * 1999-07-29 2005-10-20 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
EP1710256A1 (de) * 1999-07-29 2006-10-11 Medarex, Inc. Humane monoklonale Antikörper gegen Prostata spezifisches Membranantigen
FR2797743B1 (fr) * 1999-08-23 2003-08-08 Urogene Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
EP1221053A4 (de) * 1999-09-13 2004-12-22 Neil H Bander Verfahren zur isolierung von prostatischen epithelzellen aus sperma
JP4838436B2 (ja) * 2001-04-04 2011-12-14 積水メディカル株式会社 抗ヒト肝性トリグリセリドリパーゼ抗体
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP2360169B1 (de) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA Antikörper
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
RU2413735C2 (ru) * 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
EP1726650A1 (de) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoklonale Antikörper und Einzelkettenantikörper Fragments gegen das zelloberflächen Prostataspezifische Membranantigen
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009106101A1 (en) * 2008-02-29 2009-09-03 Interuniversitair Microelektronica Centrum Cell-enzyme based biosensors
PL2326350T3 (pl) 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
EP3495000A1 (de) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Verfahren und kits zur diagnose von krebs und vorhersage des therapeutischen werts
MX354143B (es) 2009-12-02 2018-02-14 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
TWI582112B (zh) 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
AU2012245260B2 (en) 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
PT3086814T (pt) 2013-12-23 2020-09-04 Bayer Pharma AG Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
KR20180123047A (ko) 2016-03-24 2018-11-14 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
CA3093078A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
BR112021001237A2 (pt) 2018-07-31 2021-04-27 Heidelberg Pharma Research Gmbh anticorpos humanizados contra psma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757695A3 (de) * 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostata-spezifisches Membranantigen
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
DE69635801T2 (de) * 1995-02-24 2006-11-02 Sloan-Kettering Institute For Cancer Research Prostataspezifisches membranes antigen und seine anwendungen

Also Published As

Publication number Publication date
AU725583B2 (en) 2000-10-12
DE69735294D1 (de) 2006-04-27
IL126314A0 (en) 1999-05-09
ES2260788T3 (es) 2006-11-01
JP2001503601A (ja) 2001-03-21
DE69735294T2 (de) 2006-09-21
EP0914155A1 (de) 1999-05-12
CA2250141A1 (en) 1997-10-02
AU2555297A (en) 1997-10-17
CA2250141C (en) 2008-07-29
JP4295826B2 (ja) 2009-07-15
EP0914155B1 (de) 2006-02-22
IL126314A (en) 2003-07-31
WO1997035616A1 (en) 1997-10-02
EP0914155A4 (de) 2001-05-16
DK0914155T3 (da) 2006-06-26

Similar Documents

Publication Publication Date Title
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
ES2137354T3 (es) Moleculas de anticuerpo anti-vla4 recombinante.
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
AU733544C (en) Treatment and diagnosis of cancer
ATE121130T1 (de) Monoklonaler antikörper, spezifisch gegen den funktionellen adhäsionsbereich des oberflächenproteins einer phagocyten-zelle.
PT973550E (pt) Anticorpos antagonistas anti-integrina avb3
DE69839492D1 (de) Monoklonale antikörper zur apoptosis-induzierung
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
ES2142070T3 (es) Utilizacion de un complejo ficobiliproteina-peptido de enlace como trazador fluorescente.
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
DE69028095D1 (de) M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
ATE188551T1 (de) Feststellung von antikörperproduktion
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
ATE171545T1 (de) Verfahren zur bestimmung des lysingehaltes von samen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914155

Country of ref document: EP

RZN Patent revoked